Financials data is unavailable for this security.
View more
Year on year Zelira Therapeutics Ltd 's revenues fell -82.72% from 551.26k to 95.26k. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 5.57m to a larger loss of 36.57m.
Gross margin | 91.73% |
---|---|
Net profit margin | -3,587.90% |
Operating margin | -3,587.90% |
Return on assets | -188.05% |
---|---|
Return on equity | -268.03% |
Return on investment | -246.20% |
More ▼
Cash flow in AUDView more
In 2024, Zelira Therapeutics Ltd increased its cash reserves by 300.90%, or 439.95k. Cash Flow from Financing totalled 3.92m or 4,119.28% of revenues. In addition the company used 4.39m for operations while cash from investing totalled 919.74k.
Cash flow per share | -3.20 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -0.3979 |
---|---|
Tangible book value per share | -0.4556 |
More ▼
Balance sheet in AUDView more
Current ratio | 0.6006 |
---|---|
Quick ratio | 0.424 |
Total debt/total equity | -- |
---|---|
Total debt/total capital | 3.35 |
More ▼